FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:1495-1496 October 16, 2003 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sawaya, G. F. PubMed Citation

Over the past 60 years, the mortality from cervical cancer — once one of the most common and lethal cancers in women in the United States — has decreased dramatically. Much of the reduction has been due to the widespread use of the Papanicolaou test, which has enabled clinicians to detect cervical intraepithelial neoplasia before it progresses to cervical cancer and to detect cervical cancer at an early stage. When cervical cancer is detected early, the five-year survival rate is more than 90 percent.¹ The Papanicolaou test is now the most widely used cancer-screening tool in the United States by . . . [Full Text of this Article]

Source Information

From the Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston.

This article has been cited by other articles:

• Blatter, M. M., Monk, B. J. (2008). The Pediatrician's Role in Preventing Cervical Cancer. CLIN PEDIATR 47: 627-638  
• (2003). Extending the Pap Smear Screening Interval. JWatch Women's Health 2003: 3-3 [Full Text]